Cell Death and Disease,
Journal Year:
2023,
Volume and Issue:
14(11)
Published: Nov. 1, 2023
Abstract
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
a
highly
aggressive
cancer
most
frequently
detected
at
an
advanced
stage
that
limits
treatment
options
to
systemic
chemotherapy,
which
has
provided
only
marginal
positive
clinical
outcomes.
Currently,
the
first-line
chemotherapeutic
agent
for
PDAC
gemcitabine
(GEM).
However,
chemotherapy
resistance
GEM
often
overlooked
in
of
due
lack
effective
biological
markers.
Therefore,
it
crucial
find
new
prognostic
markers
and
therapeutic
targets
patients
with
PDAC.
In
this
study,
we
identified
novel
regulatory
mechanism
development
Here,
report
LINC01134
was
significantly
upregulated
primary
tumors
from
patients.
vitro
vivo
functional
studies
revealed
promotes
through
facilitating
stem
cell
features
modulating
cycle.
Mechanistically,
interactes
tumor
suppressor
miR-497-5p
cells.
Increased
downregulates
miR-140-3p
oncogenic
WNT5A
expression.
Moreover,
m
6
A
demethylase
FTO
participated
upregulation
by
maintaining
mRNA
stability
YTHDF2.
Taken
together,
present
study
suggested
FTO-mediated
stabilization
promote
miR-140-3p/WNT5A/WNT
pathway
Our
Journal of Asian Natural Products Research,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 13
Published: Feb. 22, 2025
Esculetin
is
a
coumarin
compound
with
anticancer,
antioxidant,
and
anti-inflammatory
activities.
In
this
study,
we
synthesized
an
esculetin
derivative,
6,7-bis(Pentyloxy)-2H-Chromen-2-One
(BPCO),
through
etherification.
BPCO
inhibited
the
proliferation
of
HepG2
cells
in
dose-
time-dependent
manner.
It
also
cell
migration,
promoted
apoptosis,
caused
cycle
arrest
at
G1
phase.
Additionally,
downregulated
expression
levels
Bcl-2
Bcl-XL
upregulated
Bax
Bak.
This
study
shows
that
inhibits
hepatocellular
carcinoma
induces
providing
basis
for
further
as
antitumor
agent.
Frontiers in Oncology,
Journal Year:
2022,
Volume and Issue:
12
Published: July 8, 2022
Recently,
long
noncoding
RNA
LINC01134
has
been
shown
to
reduce
cell
viability
and
apoptosis
via
the
antioxidant
stress
pathway,
thereby
enhancing
OXA
resistance
in
hepatocellular
carcinoma.
However,
association
of
with
ferroptosis
underlying
molecular
mechanisms
remain
be
elucidated.Bioinformatics
analysis
was
employed
screen
lncRNAs
positively
correlated
GPX4
poor
clinical
prognosis.
And
Western
blot
RT-PCR
HCC
cells
confirmed
effect
on
expression.
In
addition,
siRNA
transfected
detect
changes
viability,
ROS,
lipid
peroxidation,
MDA
levels
GSH/GSSG
levels.
CCK-8,
colony
formation
assays
were
performed
determine
death.
The
Nrf2
transcriptional
binding
analyzed
using
dual
luciferase
reporter
assay
CHIP.
expression
tissues
detected
by
FISH
IHC.LINC01134
is
a
novel
lncRNA
GPx4
associated
Silenced
conferred
sensitivity
total
decreasing
ratio.
Mechanistically,
could
promote
recruitment
promoter
region
exert
regulation
GPX4.
Clinically,
or
Nrf2,
demonstrating
significance
LINC01134,
HCC.We
identified
LINC01134/Nrf2/GPX4
as
critical
axis
regulate
growth
progression.
Targeting
GPX4,
knocking
down
potential
therapeutic
strategy
for
HCC.
Current Cancer Drug Targets,
Journal Year:
2022,
Volume and Issue:
22(11), P. 865 - 878
Published: April 30, 2022
Lenvatinib
is
a
multikinase
inhibitor
which
mainly
hinders
liver
cancer
proliferation
by
inhibiting
angiogenesis.
In
2018,
was
approved
for
the
first-line
treatment
of
patients
with
advanced
hepatocellular
carcinoma
[HCC]
in
United
States,
European
Union,
Japan,
and
China.
has
been
established
as
sorafenib
replacement
drug
higher
objective
response
rate
[ORR],
longer
progression-free
survival
[PFS],
time
to
progression
[TTP].
resistance
during
become
increasingly
common
recent
years.
Accordingly,
it
necessary
determine
factors
associated
explore
solutions.
this
review,
we
sought
mechanisms
methods
reduce
summarized
achievements
treatment.
Journal of Translational Medicine,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: June 7, 2023
Abstract
Hepatocellular
carcinoma
(HCC)
is
the
leading
cause
of
cancer-related
death
in
people,
and
a
common
primary
liver
cancer.
Lacking
early
diagnosis
high
recurrence
rate
after
surgical
resection,
systemic
treatment
still
an
important
method
for
advanced
HCC.
Different
drugs
have
distinct
curative
effects,
side
effects
drug
resistance
due
to
different
properties.
At
present,
conventional
molecular
HCC
displayed
some
limitations,
such
as
adverse
reactions,
insensitivity
medicines,
resistance.
Noncoding
RNAs
(ncRNAs),
including
microRNAs
(miRNAs),
long
noncoding
(lncRNAs)
circular
(circRNAs),
been
well
documented
be
involved
occurrence
progression
Novel
biomarkers
therapeutic
targets,
research
into
basis
resistance,
are
urgently
needed
management
We
review
current
on
ncRNAs
consolidate
known
roles
regulating
examine
potential
clinical
applications
overcoming
barriers
based
targeted
therapy,
cell
cycle
non-specific
chemotherapy
specific
chemotherapy.
Biomolecules,
Journal Year:
2022,
Volume and Issue:
12(3), P. 462 - 462
Published: March 17, 2022
Epigenetic
mechanisms
are
known
to
play
a
key
role
in
cancer
progression.
Specifically,
histone
methylation
involves
reversible
post-translational
modification
of
histones
that
govern
chromatin
structure
remodelling,
genomic
imprinting,
gene
expression,
DNA
damage
repair,
and
meiotic
crossover
recombination,
among
other
chromatin-based
activities.
Demethylases
enzymes
catalyse
the
demethylation
their
substrate
using
flavin
adenine
dinucleotide-dependent
amine
oxidation
process.
Lysine-specific
demethylase
1
(LSD1)
its
homolog,
lysine-specific
2
(LSD2),
overexpressed
variety
human
types
and,
thus,
regulate
tumour
In
this
review,
we
focus
on
literature
from
last
5
years
concerning
LSD1
LSD2
main
gastrointestinal
cancers
(i.e.,
gastric
cancer,
liver
pancreatic
colorectal
cancer).
